肌醇六硫酸酯 | 23330-83-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机硫酸及其衍生物
• 中文名称: 肌醇六硫酸酯
• 英文名称: D-Myo-inositol-hexasulphate
• 英文别名: (2,3,4,5,6-pentasulfooxycyclohexyl) hydrogen sulfate
• CAS: 23330-83-8
• 化学式: C₆H₁₂O₂₄S₆
• 分子量: 660.5
• InChiKey: NBTMNFYXJYCQHQ-UHFFFAOYSA-N

物化性质

• 密度：
  2.63±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -6
• 重原子数：
  36
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  432
• 氢给体数：
  6
• 氢受体数：
  24

安全信息

• 海关编码：
  2906199090

文献信息

• [EN] 4,6-DI-(O-THIOPHOSPHATE)-INOSITOL-1,2,3,5-TETRA-O-SULFATE FOR C. DIFFICILE INFECTION<br/>[FR] 4,6-DI-(O-THIOPHOSPHATE)-INOSITOL-1,2,3,5-TÉTRA-O-SULFATE POUR UNE INFECTION À C DIFFICILE
  申请人：ETH ZÜRICH

  公开号：WO2017098033A1

  公开（公告）日：2017-06-15

  The present invention relates to inositol bisthiophosphates-tetrakissulfates, particularly for use in treating symptoms associated with Clostridium difficile infection.

  本发明涉及肌醇双硫代磷酸四硫酸酯，特别用于治疗与梭状芽孢杆菌感染相关的症状。
• OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF
  申请人：Akagera Medicines, Inc.

  公开号：US20210403463A1

  公开（公告）日：2021-12-30

  Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

  揭示了用于治疗结核病以及其他分枝杆菌和革兰氏阳性细菌感染的组合物和方法。这些组合物含有一种高效、选择性的奥沙林酮，高效地封装以最大限度地发挥低毒性药物的剂量潜力，并在血浆存在的情况下保持稳定。这些组合物在静脉注射后在循环中长时间循环，并保留其封装的药物，以便在细菌或分枝杆菌感染部位有效积累。与通常用于治疗这些感染的其他药物的每日或每日两次给药相比，结合长时间循环特性和高度稳定的药物滞留，可以实现高剂量，从而降低给药频率。
• POLYCANNABINOIDS, COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：University of Connecticut

  公开号：US20210322365A1

  公开（公告）日：2021-10-21

  Polymers comprising a plurality of cannabinoids, methods of preparation thereof, and methods of use to treat a number of disease conditions are reported. Also provided are polymer coatings, films, fibers, and non-woven fabrics for a variety of topical applications including stents, bandages, sutures, and transdermal patches.

  本文报告了包含多种大麻素的聚合物，其制备方法以及用于治疗多种疾病状况的方法。同时，还提供了用于各种局部应用的聚合物涂层、膜、纤维和无纺布，包括支架、绷带、缝合线和经皮贴片。
• PHARMACEUTICAL COMPOUNDS FOR USE IN THE THERAPY OF CLOSTRIDIUM DIFFICILE INFECTION
  申请人：ETH ZURICH

  公开号：US20140235590A1

  公开（公告）日：2014-08-21

  The invention relates to a compound described by a general formula (1), wherein each X independently can be OPO 3 2− , OPSO 2 2− or OSO 3 − ; R 1 comprises a solubility function such as a polyethylene glycol moiety and each X independently can be OPO 3 2− , OPSO 2 2− , − or OSO 3 − ; and Z is an alkyl chain comprising 1 to 3 carbon and/or hetero atoms. The invention further relates to polysulfate derivatives or mixed polyphosphate/sulphate derivatives of six-membered cyclic polyols for use in the therapy of infection by Clostridium difficile.

  本发明涉及一种由一般式（1）描述的化合物，其中每个X可以独立地是OPO32−、OPSO22−或OSO3−；R1包括诸如聚乙二醇基团之类的溶解度功能，每个X可以独立地是OPO32−、OPSO22−或OSO3−；Z是由1到3个碳和/或杂原子组成的烷基链。本发明还涉及六元环多醇的聚硫酸盐衍生物或混合聚磷酸盐/硫酸盐衍生物，用于治疗Clostridium difficile感染。
• [EN] PHARMACEUTICAL COMPOUNDS FOR USE IN THE THERAPY OF CLOSTRIDIUM DIFFICILE INFECTION<br/>[FR] COMPOSÉS PHARMACEUTIQUES POUR UTILISATION DANS LA THÉRAPIE D'UNE INFECTION PAR CLOSTRIDIUM DIFFICILE
  申请人：ETH ZUERICH

  公开号：WO2013045107A1

  公开（公告）日：2013-04-04

  The invention relates to a compound described by a general formula (1), wherein each X independently can be OPO32-, OPSO22- or OSO3-; R1 comprises a solubility function such as a polyethylene glycol moiety and each X independently can be OPO32-, OPSO22-, - or OSO3-; and Z is an alkyl chain comprising 1 to 3 carbon and/or hetero atoms. The invention further relates to polysulfate derivatives or mixed polyphosphate/sulphate derivatives of six-membered cyclic polyols for use in the therapy of infection by Clostridium difficile.

  本发明涉及一种由普遍式（1）描述的化合物，其中每个X独立地可以是OPO32-，OPSO22-或OSO3-；R1包括溶解性功能，例如聚乙二醇基团，每个X独立地可以是OPO32-，OPSO22-或OSO3-；而Z是一个含有1到3个碳和/或杂原子的烷基链。本发明还涉及六元环多元硫酸盐衍生物或混合多聚磷酸盐/硫酸盐衍生物，用于治疗难辨梭菌感染。